JP2019099571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019099571A5 JP2019099571A5 JP2018223465A JP2018223465A JP2019099571A5 JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024045935A JP2024079762A (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017228661 | 2017-11-29 | ||
| JP2017228661 | 2017-11-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045935A Division JP2024079762A (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019099571A JP2019099571A (ja) | 2019-06-24 |
| JP2019099571A5 true JP2019099571A5 (enrdf_load_html_response) | 2022-01-06 |
| JP7461104B2 JP7461104B2 (ja) | 2024-04-03 |
Family
ID=66975925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018223465A Active JP7461104B2 (ja) | 2017-11-29 | 2018-11-29 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP2024045935A Pending JP2024079762A (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045935A Pending JP2024079762A (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7461104B2 (enrdf_load_html_response) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110618208A (zh) * | 2019-09-10 | 2019-12-27 | 威海迪素制药有限公司 | 一种（s）-（+）-3-羟基四氢呋喃对映异构体含量检测方法 |
| CR20220371A (es) * | 2020-02-07 | 2022-10-27 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| WO2022048665A1 (en) * | 2020-09-07 | 2022-03-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022052958A1 (en) * | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20240366639A1 (en) * | 2021-08-12 | 2024-11-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| IL311667A (en) | 2021-09-27 | 2024-05-01 | Terns Pharmaceuticals Inc | Benzimidazole carboxylic acids as GLP-1R agonists |
| PE20250741A1 (es) | 2022-02-23 | 2025-03-13 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| EP4522131A1 (en) * | 2022-05-11 | 2025-03-19 | Eli Lilly and Company | Glp1 tablet compositions |
| WO2023220109A1 (en) * | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 pharmaceutical compositions |
| AU2023397781A1 (en) * | 2022-12-13 | 2025-06-26 | Eli Lilly And Company | Dosage regime of orforglipron for treating a subject with type 2 diabetes (t2d), obesity, or overweight with at least one weight related comorbidity |
| WO2024125624A1 (en) * | 2022-12-15 | 2024-06-20 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| CN120659776A (zh) | 2022-12-19 | 2025-09-16 | 伊莱利利公司 | Glp1 ra及其中间体的制备方法 |
| WO2024153070A1 (en) * | 2023-01-17 | 2024-07-25 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202502322A (zh) * | 2023-06-29 | 2025-01-16 | 大陸商韋恩生物科技有限公司 | 一種glp-1受體激動劑及其製備方法和用途 |
| TW202506108A (zh) * | 2023-06-30 | 2025-02-16 | 大陸商正大天晴藥業集團股份有限公司 | 含多稠環結構的化合物 |
| CN119431365A (zh) * | 2023-07-28 | 2025-02-14 | 江苏豪森药业集团有限公司 | 一种含苯基杂环类衍生物调节剂及其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025097835A1 (zh) * | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0313880B8 (pt) | 2002-08-26 | 2021-05-25 | Takeda Pharmaceuticals Co | composto |
| CA2670636A1 (en) | 2006-11-27 | 2008-06-05 | H. Lundbeck A/S | Heteroaryl amide derivatives |
| EA023430B1 (ru) | 2009-03-30 | 2016-06-30 | виТиви ТЕРАПЬЮТИКС ЭлЭлСи | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения |
| WO2014122067A1 (en) | 2013-02-06 | 2014-08-14 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| EP2993174A1 (en) | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
-
2018
- 2018-11-29 JP JP2018223465A patent/JP7461104B2/ja active Active
-
2024
- 2024-03-22 JP JP2024045935A patent/JP2024079762A/ja active Pending